The influence of patient beliefs and treatment satisfaction on the discontinuation of current first-line antiretroviral regimens

HIV Medicine ◽  
2015 ◽  
Vol 17 (1) ◽  
pp. 46-55 ◽  
Author(s):  
JL Casado ◽  
A Marín ◽  
V Romero ◽  
S Bañón ◽  
A Moreno ◽  
...  
Keyword(s):  
Treatment Satisfaction ◽  
First Line ◽  
Patient Beliefs

Improved treatment satisfaction after switching therapy to rituximab in relapsing–remitting MS

2016 ◽  
Vol 23 (9) ◽  
pp. 1249-1257 ◽  
Author(s):  
Pierre de Flon ◽  
Katarina Laurell ◽  
Lars Söderström ◽  
Martin Gunnarsson ◽  
Anders Svenningsson
Keyword(s):  
Multiple Sclerosis ◽  
Disease Progression ◽  
Treatment Satisfaction ◽  
Treatment Strategies ◽  
First Line ◽  
Open Label ◽  
Immunomodulating Therapy ◽  
Patient Reported ◽  
Relapsing Remitting ◽  
Perceived Impact

Objective: New disease-modifying treatment strategies in multiple sclerosis offer possibilities for individualised treatment. In this study, we evaluated patient-reported outcome measures before and after a switch in therapy from first-line injectable treatments to rituximab. Method: A total of 75 patients with clinically stable relapsing–remitting multiple sclerosis (RRMS) receiving ongoing first-line injectable treatment at three Swedish centres had their treatment switched to rituximab in this open-label phase II multicentre study. Assessment of treatment satisfaction, patient-perceived impact of the disease on daily life, fatigue, cognitive symptoms and disease progression was performed 3 months before and at the time of the treatment shift and then for a subsequent 2-year period. Results: The overall treatment satisfaction rating improved significantly from a mean of 4.8 (scale range: 1–7), while on injectable therapies, to a mean of 6.3 after 1 year of rituximab treatment ( p < 0.001). This improvement was sustained after 2 years. There was no significant change in scores for patient-perceived impact of disease, fatigue or disease progression. Conclusion: A shift in therapy from first-line injectables to rituximab in a cohort of clinically stable RRMS patients was followed by improved treatment satisfaction. This is clinically relevant as it may influence long-term adherence to immunomodulating therapy.

1664: Androgen Metabolism Genotypes as Predictors of PSA Progression and First line Hormonal Deprivation Failure

2004 ◽  
Vol 171 (4S) ◽  
pp. 440-440
Author(s):  
Fernando J. Bianco ◽  
Mark B. Fisher ◽  
Michael L. Cher ◽  
Richard Everson ◽  
Wael A. Sakr ◽  
...  
Keyword(s):  
First Line ◽  
Androgen Metabolism ◽  
Psa Progression

1904: Outcomes of Large Renal Calculi (>2-Cm) Treated with ESWL as First Line Therapy

2004 ◽  
Vol 171 (4S) ◽  
pp. 503-503
Author(s):  
Richard Vanlangendock ◽  
Ramakrishna Venkatesh ◽  
Jamil Rehman ◽  
Chandra P. Sundaram ◽  
Jaime Landman
Keyword(s):  
Renal Calculi ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

First-Line Methotrexate Upheld by Euro Panel

2009 ◽  
Vol 40 (9) ◽  
pp. 32
Author(s):  
MITCHEL L. ZOLER
Keyword(s):  
First Line
Sign in / Sign up

Export Citation Format

Share Document